Risk factors of extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia in Thai emergency department: A retrospective case-control study

Asian Biomedicine

Volumn 5, Issue 1, 2011, Pages 129-138

  Musikatavorn, Khrongwong ^a   Chumpengpan, Chatgaew ^b   Sujinpram, Chaita ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Bacteremia; Emergency department; Extended spectrum beta lactamase; Risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULPERAZON;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; EMERGENCY WARD; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; FUNCTIONAL STATUS; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEOPLASM; NONHUMAN; RETROSPECTIVE STUDY; THAILAND;

EID: 79961174149     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.5372/1905-7415.0501.016     Document Type: Article

References (35)

1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589-96. (Pubitemid 43810035)
2. Dellinger RP, Levy MM, Carlet JM, Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36:296-327.
3. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J ClinMicrobiol Infect Dis. 2004; 23:163-7. (Pubitemid 38471420)
4. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajad JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897-902.
5. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis. 2003; 9:1024-5.
6. Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtaş M, Gürcüoglu E, et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother. 2008; 20:581-5.
7. Ling TK, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM. Multicenter antimicrobial susceptibility survey of gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China. Antimicrob Agents Chemother. 2006; 50:41-67.
8. Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2008; 27:85-8. (Pubitemid 350197875)
9. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control. 2007; 35:606-12. (Pubitemid 350007843)
10. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31(Suppl 4):S131-8 (Pubitemid 32291120)
11. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcome in the ICU setting. Chest. 2000; 118:146-55. (Pubitemid 30485502)
12. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007; 55:254-9. (Pubitemid 47244918)
13. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001; 32:1162-71. (Pubitemid 32390110)
14. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia:Churchill Livingston; 2009, p. 957-85.
15. Donowitz GR. Pleuropulmonary and bronchial infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingston; 2009, p. 891-916.
16. Sifri CD, Madoff LC. Intra-abdominal infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia:Churchill Livingston; 2009, p. 1035-44.
17. Pasternack MS, Swartz MN. Skin and soft tissue infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingston; 2009, p. 1289-312.
18. CLSI (NCCLS). Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S18. Vol. 28. Wayne:Clinical Laboratory Standards Institute; 2008.
19. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996; 48:907-16. (Pubitemid 26283404)
20. Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of extended-spectrum beta-lactamaseproducing gramnegative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health. 2005; 36:1503-9. (Pubitemid 43416128)
21. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase-producing Escherichia coli in Thailand. Infect Control Hosp Epidemiol. 2008;29:80-2. (Pubitemid 351267781)
22. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-7. (Pubitemid 38879546)
23. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentn C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682-90.
24. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006; 57:780-3.
25. Martínez JA, Aguilar J, Almela M, Marco F, Soriano A, López F, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase- producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother. 2006;58:1082-5.
26. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791-7. (Pubitemid 35334450)
27. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruíz M, Peña C, et al. Spanish network for research in infectious diseases (REIPI). Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010; 50:40-8.
28. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001; 32:1055-61. (Pubitemid 32299641)
29. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002; 34:1558-63. (Pubitemid 34615439)
30. Behar PR, Teixeira PJ, Fachel JM, Kalil AC. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J Hosp Infect. 2008; 68:123-9. (Pubitemid 351209313)
31. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterialcystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999; 29:745-58. (Pubitemid 30256361)
32. Dow G, Rao P, Harding G, Brunka J, Kennedy J, Alfa M, et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis. 2004; 39:658-64. (Pubitemid 39180437)
33. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiellapneumoniae isolates causing bacteremia. Clin Infect Dis. 2000; 30:473-8. (Pubitemid 30205291)
34. Oktem IM, Gulay Z, Bicmen M, Gur D. HITIT Project Study Group. qnrA prevalence in extended-spectrum beta-lactamase-positive Enterobacteriaceae isolates from Turkey. Jpn J Infect Dis. 2008; 61:13-7. (Pubitemid 351338524)
35. LavillaS, Gonzalez-Lopez JJ, Sabate M, Garcia-Fernandez A, Larrosa MN, Bartolome RM, et al. Prevalence of qnr genes among extended-spectrum beta-lactamase-producing enterobacterial isolates in Barcelona, Spain. J Antimicrob Chemother. 2008; 61:291-5.